Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Shamash

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
BJU International|February 9, 2008
Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumourYasser Haba, Michael V Williams, David E Neal, et al.
The Prostate|March 19, 2025
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate-Resistant Prostate Cancer (TRICREST)Kenrick Ng, Garima Priyadarshini, Shah-Jalal Sarker, et al.
Clinical Genitourinary Cancer|December 3, 2025
GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment RegimenKenrick Ng, Garima Priyadarshini, Aaron Prendergast, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2005
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesotheliomaDean A Fennell, Jeremy P C Steele, Jonathan Shamash, et al.
Frontiers in Oncology|November 13, 2023
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapyGeorgina E Wood, Christopher P Bunting, Mesel Veli, et al.
American Journal of Cancer Research|June 21, 2019
The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumorsMarc Yeste-Velasco, Tianyu Guo, Xueying Mao, et al.
Acta Oncologica (Stockholm, Sweden)|September 5, 2012
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminomaLaura Tookman, Sukaina Rashid, Athena Matakidou, et al.
Eclinicalmedicine|March 28, 2024
Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspectiveFarzana Pashankar, Matthew J Murray, Joanna Gell, et al.
British Journal of Cancer|September 29, 2020
The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG)Jonathan Shamash, Wendy Ansell, Constantine Alifrangis, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 22, 2022
Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort studyRadha Graham, Nicola D MacDonald, Michelle Lockley, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
BJU International|February 9, 2008
Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumourYasser Haba, Michael V Williams, David E Neal, et al.
The Prostate|March 19, 2025
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate-Resistant Prostate Cancer (TRICREST)Kenrick Ng, Garima Priyadarshini, Shah-Jalal Sarker, et al.
Clinical Genitourinary Cancer|December 3, 2025
GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment RegimenKenrick Ng, Garima Priyadarshini, Aaron Prendergast, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2005
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesotheliomaDean A Fennell, Jeremy P C Steele, Jonathan Shamash, et al.
Frontiers in Oncology|November 13, 2023
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapyGeorgina E Wood, Christopher P Bunting, Mesel Veli, et al.
American Journal of Cancer Research|June 21, 2019
The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumorsMarc Yeste-Velasco, Tianyu Guo, Xueying Mao, et al.
Acta Oncologica (Stockholm, Sweden)|September 5, 2012
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminomaLaura Tookman, Sukaina Rashid, Athena Matakidou, et al.
Eclinicalmedicine|March 28, 2024
Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspectiveFarzana Pashankar, Matthew J Murray, Joanna Gell, et al.
British Journal of Cancer|September 29, 2020
The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG)Jonathan Shamash, Wendy Ansell, Constantine Alifrangis, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 22, 2022
Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort studyRadha Graham, Nicola D MacDonald, Michelle Lockley, et al.
Pageof 11